These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26475967)

  • 1. Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP.
    Pan L; Zeng K; Wang X; Bi H; Hu H; Huang M; Lou Y; Zeng S
    Int J Pharm; 2015 Dec; 496(2):440-7. PubMed ID: 26475967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibition mechanism of the uptake of lamivudine via human organic anion transporter 1 by Stellera chamaejasme L. extracts.
    Pan LY; Zeng K; Li L; Lou Y; Zeng S
    Chin J Nat Med; 2019 Sep; 17(9):682-689. PubMed ID: 31526503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
    Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
    J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
    Xiao L; Yi T; Chen M; Lam CW; Zhou H
    Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.
    Li L; Yao QQ; Xu SY; Hu HH; Shen Q; Tian Y; Pan LY; Zhou H; Jiang HD; Lu C; Yu LS; Zeng S
    Eur J Pharm Biopharm; 2014 Nov; 88(3):759-67. PubMed ID: 24980806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
    Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
    J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of neochamaejasmin B on P-glycoprotein in MDCK-hMDR1 cells and molecular docking of NCB binding in P-glycoprotein.
    Pan L; Hu H; Wang X; Yu L; Jiang H; Chen J; Lou Y; Zeng S
    Molecules; 2015 Feb; 20(2):2931-48. PubMed ID: 25679052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of terpenoids on multidrug resistance-associated protein 2- and breast cancer resistance protein-mediated transport.
    Yoshida N; Takada T; Yamamura Y; Adachi I; Suzuki H; Kawakami J
    Drug Metab Dispos; 2008 Jul; 36(7):1206-11. PubMed ID: 18436619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.
    Lagas JS; van der Kruijssen CM; van de Wetering K; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2009 Jan; 37(1):129-36. PubMed ID: 18845662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP.
    Ge S; Yin T; Xu B; Gao S; Hu M
    Pharm Res; 2016 Mar; 33(3):590-602. PubMed ID: 26502886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
    Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolites characterization of chamaechromone in vivo and in vitro by using ultra-performance liquid chromatography/Xevo G2 quadrupole time-of-flight tandem mass spectrometry.
    Lou Y; Zheng J; Wang B; Zhang X; Zhang X; Zeng S
    J Ethnopharmacol; 2014; 151(1):242-52. PubMed ID: 24189033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
    Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.
    Sato S; Tohyama K; Kosugi Y
    Eur J Pharm Sci; 2020 Jan; 142():105119. PubMed ID: 31682973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
    Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
    Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
    Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
    J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K; Sane R; Podila L; Taub ME
    J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
    Zhang S; Wang X; Sagawa K; Morris ME
    Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The need for human breast cancer resistance protein substrate and inhibition evaluation in drug discovery and development: why, when, and how?
    Poirier A; Portmann R; Cascais AC; Bader U; Walter I; Ullah M; Funk C
    Drug Metab Dispos; 2014 Sep; 42(9):1466-77. PubMed ID: 24989889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.